Haemonetics
298 hedge funds and large institutions have $4.37B invested in Haemonetics in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 104 increasing their positions, 115 reducing their positions, and 40 closing their positions.
190% more call options, than puts
Call options by funds: $14.6M | Put options by funds: $5.04M
1% more funds holding
Funds holding: 295 → 298 (+3)
8% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 40
0.26% more ownership
Funds ownership: 100.53% → 100.79% (+0.26%)
0% more capital invested
Capital invested by funds: $4.36B → $4.37B (+$6.27M)
10% less repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 115
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$78.7M |
| 2 |
SAM
Silvercrest Asset Management
New York
|
+$35.6M |
| 3 |
RA
Royce & Associates
New York
|
+$23.6M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$22.5M |
| 5 |
Neuberger Berman Group
New York
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$109M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$48.4M |
| 3 |
Morgan Stanley
New York
|
-$44.5M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$23.6M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
-$20.7M |
HAE Hedge Fund Activity: Q1 2024 in Review
298 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q1 2024, worth a combined $4.37B — up 0.14% from $4.36B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new HAE positions and 40 closed out — a net gain of 3 holders — while 104 added to existing stakes and 115 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $78.7M. The largest seller was Fidelity Investments, cutting an estimated $109M.
- 298 institutional investors held Haemonetics (HAE) as of Q1 2024, up from 295 in Q4 2023.
- Funds reported $4.37B of Haemonetics stock for Q1 2024, up 0.14% quarter-over-quarter.
- 43 funds opened new Haemonetics positions in Q1 2024 and 40 closed out, a net change of +3 holders.
- The largest Haemonetics buyer in Q1 2024 was Wellington Management Group, an estimated $78.7M added.
- The largest Haemonetics seller in Q1 2024 was Fidelity Investments, an estimated $109M sold.
Based on aggregated 13F filings for Q1 2024.